These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Roles of tumor heterogeneity in the development of drug resistance: A call for precision therapy. Wu D; Wang DC; Cheng Y; Qian M; Zhang M; Shen Q; Wang X Semin Cancer Biol; 2017 Feb; 42():13-19. PubMed ID: 27840278 [TBL] [Abstract][Full Text] [Related]
11. Understanding resistance to targeted cancer drugs through loss of function genetic screens. Berns K; Bernards R Drug Resist Updat; 2012 Oct; 15(5-6):268-75. PubMed ID: 23142522 [TBL] [Abstract][Full Text] [Related]
12. Cancer Drug Resistance: A Brief Overview from a Genetic Viewpoint. Rueff J; Rodrigues AS Methods Mol Biol; 2016; 1395():1-18. PubMed ID: 26910065 [TBL] [Abstract][Full Text] [Related]
13. Implications of cancer evolution for drug development. Turajlic S; Swanton C Nat Rev Drug Discov; 2017 Jul; 16(7):441-442. PubMed ID: 28450743 [No Abstract] [Full Text] [Related]
14. Tumor progression: chance and necessity in Darwinian and Lamarckian somatic (mutationless) evolution. Huang S Prog Biophys Mol Biol; 2012 Sep; 110(1):69-86. PubMed ID: 22579660 [TBL] [Abstract][Full Text] [Related]
15. New strategies for targeting drug combinations to overcome mutation-driven drug resistance. Wang L; Wang H; Song D; Xu M; Liebmen M Semin Cancer Biol; 2017 Feb; 42():44-51. PubMed ID: 27840276 [TBL] [Abstract][Full Text] [Related]
16. Mechanism-based cancer therapy: resistance to therapy, therapy for resistance. Ramos P; Bentires-Alj M Oncogene; 2015 Jul; 34(28):3617-26. PubMed ID: 25263438 [TBL] [Abstract][Full Text] [Related]